Index

Note: Page references followed by an ‘f’ refer to Figures; those followed by a ‘t’ refer to Tables.

A and B subgroups. See Blood groups
Abbreviated (ABO) crossmatch, 221–222
ABH genes, 177f, 179t
ABO and Rh
in platelet transfusion, 268–270
typing, 218, 219t
ABO antigens, 219t, 235–236
ABO-incompatible transplants, 319–322, 320f, 320t
ABO system, 174–181, 178t, 179t
ABO typing, 149–151, 151t, 152t
discrepancies, causes of, 152t
Acetaminophen, 384
Acid-base balance, 313
Acid-base imbalance, 400
Acid-citrate-dextrose (ACD), 78, 503
Acidosis, 336
Acquired immune deficiency syndrome (AIDS), 279, 476–477, 480.
See also Transfusion therapy
Activated natural killer cells, 505
Active bleeding, treatment of, 265–268, 267t
Acute blood loss, 305t
See also Transfusion therapy
Acute chest syndrome, 91
Acute lung injury (ALI), 385–387, 386t
Acute lymphocytic leukemia (ALL), 505
Acute myelogenous leukemia (AML), 505
Acute normovolemic hemodilution (ANH), 103, 110–112, 111t, 112t
Additive solutions, 70t
Adenosine triphosphate (ATP), 8, 69
Adoptive immunotherapy, 504–7
Antiviral immunotherapy, 506
cytomegalovirus, 506
dendritic cells, 505–506
Epstein–Barr virus
lymphoproliferative disorders, 506–507
natural killer and activated natural killer cells, 505
peripheral blood mononuclear cells, 505
T-regulatory cells, 504–505
Adsol, 252
Adsorbance measurement, 233
Adsorption columns, 548–550
Adult respiratory distress syndrome (ARDS), 314, 401, 542
Adult T-cell leukemia (ATL), 423–424
Affinity column, 215
African trypanosomiasis, 432
Age of blood donors, 28–29
Agglutination, 211
AIDS. See Acquired immune deficiency syndrome (AIDS)
AIHA. See Autoimmune hemolytic anemia (AIHA)
Air embolus, 59–60
Alanine aminotransferase (ALT), 156, 161–162, 417–418
Index

Albumin, 538–539
Alcohol, 52
Allergic reactions, 385
Alloantigens, 185, 201
Allogeneic bone marrow transplantation, 284
Allogeneic hematopoietic stem cell transplantation, 459–460
Allogeneic transfusion, 103, 106
Alloimmune platelet refractoriness, 463, 533
Alloimmunization, 75, 76, 82, 201, 268, 272f, 461 prevention, 270, 274
ALT. See Alanine aminotransferase (ALT)
America’s Blood Centers (ABC), 21–22
American Association of Blood Banks (AABB), 18, 20–21, 115, 153, 231, 250 Quality program, 563t, 565–9
American Instrument Company, 125
American Medical Association (AMA), 4, 521
American Red Cross, 21, 34, 425
Rare Donor Registries, 231, 250, 345
American Society of Hematology, 20
Aminco Celltrifuge, 125
Amino acid, 451
Amyotrophic lateral sclerosis (ALS), 530
Anaphylactic reactions, 387
Anemia in AIDS, 340
aplastic, 262
of chronic disease, 475–476
physiologic responses to, 243t
of prematurity, 477
preoperative, detection and management, 102–3
Angiotensin-converting enzyme (ACE) inhibitors, 543–544
Animal-to-animal transfusions, 2
Antibody of ABH system, 181
platelet-specific, 166
to red cell antigens, 195–196, 196t screening test, 221t
Anticoagulant citrate dextrose (ACD), 59, 128
Anticoagulant, 4–5, 59, 113 preservative solutions, 50, 69, 69t, 70t
Antigen-antibody reaction detection, 211
affinity column, 215
gel test, 214
slide/tile typing, 214
solid-phase tests, 214
tube tests, 215
Antigen-antibody reaction enhancement, 212
antihuman globulin (AHG) serum, 212 enzymes, 213
low-ionic-strength solution (LISS), 213 polybrene, 213 polyethylene glycol (PEG), 213
Antigen-presenting cells (APC), 448
Antigens, 166 detection tests, 428 distribution and subgroups, 180 Antiglobulin serum, 6–7
Anti-HIV-1-positive blood transfusion, 422
Anti-HIV-negative blood (window phase) transfusion, 421
Antihuman globulin (AHG), 152, 154, 212, 220f
Antitumor immunotherapy, 506
Antiviral immunotherapy, 506
Apheresis donors adverse reactions in, 58, 58t air embolus, 59–60 anticoagulation, 59 circulatory effects, 59 citrate toxicity, 59 hematoma, 60 leukapheresis, complications in, 61
lymphocyte depletion, 60–61 mechanical hemolysis, 60 mononuclear cell apheresis, complications in, 62 plasmapheresis, complications in, 61 platelet depletion/damage, 60 vasovagal reactions, 59 medical assessment of allogeneic donors, 58 blood volume shifts, 57
Apheresis donors (cont’d)
  physical examination of, 58
  platelethpheresis donors, 56
  red cell loss, 56
  serial donations, complications of, 57–58
  recruitment of, 36
Apheresis, 9
  procedure, 543–544
Apheresis, component production by, 122–123, 124t
  centrifugation instrument for
cytapheresis
    continuous-flow centrifugation, 125–126
    intermittent-flow centrifugation, 123–125
cytapheresis, 135–140, 137t, 138t, 139f (See also Peripheral blood stem cells (PBSC))
instruments
  Fresenius Kabi Alyx, 127
  Fresenius Kabi Amicus, 126–127
  Fresenius Kabi AS, 104, 129
  Haemonetics system, 128–129, 128f
  Terumo Trima AccelTM, 127–128
leukapheresis, 131–132
  donor-recipient matching, 134
  filtration leukapheresis (FL), 133
  granulocytes, function of, 133
  granulocytes, storage of, 133–134
  hydroxyethyl starch in, 132
  stimulation of donors with corticosteroid or G-CSF, 132–133
  lymphocytophthesis, 134–135
  plateletpheresis, 129–130
  red cell collection, 130–131, 131t
  See also Therapeutic apheresis
Aplastic anemia, 262, 285, 480
Arterial puncture, 55
Arthur D. Little Corporation (ADL), 123
Attribution/self-perception framework, 30
Audit
  internal quality, 568
  transfusion, 573–574
Autoantibodies, 336
Autoimmune diseases, 507
Autoimmune hemolytic anemia (AIHA), 322, 339t, 533
Autoimmune neutropenia (AIN), 345
Autoimmune thrombocytopenia, 201, 262, 342–343, 533
Autoimmune thrombocytopenic purpura, 87, 267
Autologous blood donation,
  preoperative, 103–106, 104t
  acute normovolemic hemodilution (ANH), 103, 110–112, 111t, 112t
  postoperative salvage, 103, 114–15
Autologous bone marrow transplantation, 284
Automated testing systems for infectious disease, 157t

Babesia bovis, 429
Babesia microti, 165, 429
Babesiosis, 165, 429, 535
BacT/ALERT system, 164
Bacteremia, 114
Bacteria, detection of, 164–165
Bacterial contamination, transfusion-transmitted, 389–91, 390t
Bacterial infections. See Transfusion-transmitted diseases
Baxter Corporation, 7
Baxter CS-3000, 126
Becker's model of commitment, 30
Bilirubin, 211
Bleeding prevention. See Prophylaxis
Bleeding tendency, 400
Blood banking and transfusion medicine, 5
  components produced by, 68t
  errors in transfusion medicine, 569–570
  procedures, 306–307, 413t
  quality assurance in transfusion therapy, 570–4
  audit, transfusion, 573–574
  blood management programs, 573
  blood ordering practices, 573
  blood supply, 570t, 571
  hospital transfusion service, 571–572, 571t
  medical indications, 573
  physician education, 574
quality assurance in patient
therapy, 572
transfusion committee, 574
transfusion procedures, 572
quality systems in blood supply
adverse reaction files, 568
American Association of Blood
Banks Quality program, 565–569
computers and information
systems, 567
critical control points, 569
customer focus, 566
documents and records, 566
equipment, 566
facilities work environment and
safety, 565–566
human resources, 566–567
internal quality audits, 568
International Organization for
Standardization, 564
labeling, 566
laboratory quality controls, 569
nonconforming event
management, 567
organization and leadership, 565
process improvement, 568
records management, 567
standard operating procedures
(SOPs), 568
supplies and material
management, 566
quality and quality assurance
systems, 560–564, 561t, 562t,
563t, 564t
quality assurance in blood supply
system, 564–569
Blood cell separators, 122
Blood collection, 51–52
amount, 16–18
Containers, 49, 50
cord, 503–504
whole, 41–42, 49–52
Blood components, 7–8
blood substitutes, 90–91
hemoglobin substitutes, impact
of, 90–91
potential clinical uses, 91
identification, 365–366, 366t
irradiation of, 82, 281–282
outline of, 67, 68t
pathogen-inactivated, 87
fresh frozen plasma (FFP), 87–88
platelets, 88–89
red cells, 89
solvent–detergent plasma
(Octoplas), 87, 88t
universal red cells, 89–90
preparation from whole blood
anticoagulant–preservative
solutions, 69, 70t, 71t
blood processing, 69–71, 71f
cryoprecipitate, 78–79
fresh frozen plasma (FFP), 77–78
frozen or deglycerolized red
blood cells, 73–75
granulocytes, 82
24-hour frozen plasma (FP24), 77
leukocyte-reduced red blood
cells, 75–77, 76t
plasma, 78
platelet concentrates (whole
blood), 79–82, 79t, 80f
red blood cells, 72–73, 72t
washed red cells, 75
utilization, 320t
Blood components, clinical uses of
blood component therapy, 242
cytomegalovirus-safe blood
components, 276–280
acquired immune deficiency
syndrome (AIDS), 279
bone marrow transplantation,
278–279
chemotherapy, extensive, 280
heart/heart–lung/liver/pancreas
transplantation, 279
kidney transplantation, 277–278
neonates, 277
pregnant women, 277
severe combined immune
deficiency (congenital),
279–280
irradiated blood components
graft-versus-host disease
(GVHD), 281–282
indications for, 284–7
irradiation, 281–282
leukocyte depletion, 283
pathogen inactivation and
prevention of GVHD, 283–284
quality control of irradiation, 283
Blood components, clinical uses of (cont’d)
   storage of, 282–283
   therapeutic agents containing coagulation factors
     ABO and Rh in platelet transfusion, 268–270
   bleeding (prophylaxis)
     prevention, 265–268, 267f, 271–274, 272f, 273t
   blood group compatibility, 262
   crossmatching for platelet transfusion, 272–273
   cryoprecipitate, 254–255
   fibrinogen, 261
   fibrin sealant (glue), 255, 256t, 257t
   fresh frozen plasma (FFP), 252, 253, 253t, 257–258
   24-hour plasma (FP-24), 252, 253
   multiple coagulation factors, deficiency of, 255–259
   plasma, 254
   prophylaxis for invasive procedures, 268
   single coagulation factors, deficiency of, 259–262
   solvent–detergent plasma, 254
   transfusion of components
     bloodless medicine, 245, 245t
     frozen deglycerolized red blood cells, 250
     leukocyte-reduced red cells, 247–249, 247t, 248t
     physiology in red cell transfusion decisions, 242–244, 243t
     red blood cell components, use of, 246–250
     red blood cell transfusion, effects of, 251–252
     red blood cell transfusion trigger, 244–245
     red cells, clinical uses of, 246
     stored red blood cells, clinical effects of, 246
     washed red cells, 249–250
     whole blood, 247

Blood donation
   by infectious patient, 108–109
   directed donors, 115, 116
   patient-specific, 116
   severe reactions to, 54

See also Preoperative autologous donor blood

Blood donor medical assessment
   apheresis donors
     adverse reactions in, 58–62
     medical assessment of, 42, 42t, 55–58
   whole blood, collection of
     anticoagulant preservative solutions, 50
     blood collection, 51–52
     blood containers, 49–50
     labeling, 49
     vein selection, 50
     venipuncture, 51
     venipuncture site preparation, 50, 50t
   whole blood donation, adverse reactions to, 52–55, 53t
     arterial puncture, 55
     hematoma, 55
     nerve injuries, 54
     postdonation care, 52
     seizures, 54
     severe reactions to blood donation, 54
     therapeutic bleeding, 55
     thrombosis, 55
   whole blood donors, medical assessment of, 42, 42t
     hemochromatosis patients as blood donors, 47
     medical history, 43–47, 44–45t
     physical examination of blood donor, 47–49
     registration, 42–43
     special blood donations, 49

Blood donors
   hemochromatosis patients as, 47
   medical history questions for, 44–45t

Blood donors, recruitment of
   apheresis donor recruitment, 36
   bone marrow donors, 36–37
   demographic characteristics of
     age, 29
     education and socioeconomic characteristics, 29
     employment, 30
     gender, 28–29
race/ethnicity, 29
social characteristics, 30
donation experience, 32
donation situation, 33
family history of donation, 33
incentives, role of, 34
organizational influences, 33–34
social influences on blood
donation, 32–33
whole blood donor recruitment
strategies, 34–35
whole blood donors, motivation of,
31
integrated model, 30–31
planned behavior theory, 31
psychosocial theories, 30
reasons for donation, 31
Blood groups
ABO system, 174–181, 178t, 179t
genes and composition, 177–179
antibodies, 324
antibodies to red cell antigens,
195–196, 196t
A and B subgroups, 179–180
antibodies of ABH system, 181
antigen distribution and subgroups,
180
Bombay type, 180
compatibility, 262
discovery of, 4, 181–182
granulocytes, 204–206, 205t
laboratory detection of (See
Laboratory detection of blood
groups)
molecules, function of, 196, 198,
199t
complement regulatory
molecules, 199–200
enzymatic activity, 200
microbial receptor, 200
receptors and adhesion
molecules, 198–199
red cell function, 198, 199t
red cell structure, 197–198, 198t
transport protein, 199
platelets, 200–204, 202–203t, 204t
red cell blood groups, 173, 174t,
175–176t, 177f, 178f
Catwright (Yt), 192
Colton (Co) system, 192
Cromer (Cr) system, 193
Diego (Di) system, 191–192
Dombrock (Do) system, 192
Duffy system, 186–187
Gerbich (Ge) system, 193
GIL antigen, 194
II blood group antigens, 194–195
Indian (In) system, 193–194
JMH system, 194
Kell system, 185–186
Kidd system, 187
Knops (Kn) system, 193
Lewis system, 190–191
Lutheran system, 188
LW system, 191
MN system, 188–189
OK system, 194
P system, 189–190
RAPH system, 194
Rogers (Rg) and chido (Ch)
system, 193
Scianna (Sc) system, 192
Xg system, 192
Rh system
antibodies, 184, 185t
discovery, 181–182
nomenclature and genetics, 182,
183t
null type, 184
structure and composition of D
antigen, 182–183
weak D, D variant, Du, and
partial D, 182–183
see also Human leukocyte antigens
(HLA)
Blood Safety and Clinical Technology,
22
Blood salvage
intraoperative, 112–114, 113t
postoperative, 114–115
Blood supply, 570t, 571
availability, 226–228, 227t, 230
and safety, 14t
blood sharing, 18
community blood centers, activities
of, 18–19
nongovernmental blood bank
organizations
American Association of Blood
Banks (AABB), 20–21
America’s Blood Centers (ABC),
21–22
Blood supply (cont’d)
Federation of Red Cross and Red Crescent Societies, 22
International Society for Blood Transfusion (ISBT), 22–23
Plasma Protein Therapeutics Association (PPTA), 22
World Health Organization (WHO), 22
plasma collection system
federally licensed, 20
plasma, definitions of, 19
plasma collection activity, 20
regulation of
CAP accreditation program, 25–26
licensure, 25
United States Federal Regulation, 23–25
voluntary accreditation of blood banks, 25
worldwide, 13–15, 14t
Blood transfusion, techniques of, 361t
blood administration sets and filters, 363–364
blood component identification, 365–366, 366t
blood sample for compatibility testing, 361–362
for children and neonates, 370–371
consent, obtaining, 360–361
hematopoietic stem cell products, 371–373, 372t
infusion pumps, 369
infusion solutions, 365
in nonhospital setting, 373
nursing care of patients, 369–370
patient identification, 365–366, 366t
platelets and plasma, 371
rate and duration of, 367
transfusion, start of, 366–367
venous access and venipuncture, 364
warming of blood, 367–368, 368t
Blood sampling
for compatibility test, 361–362
identification of, 217
for laboratory tests, 314
Blood use monitoring, 102
Bloodless medicine, 245, 245t
Blundell, James, 3
Bombay phenotype, 180
Bone marrow, 498–9, 499t
collection, 496–7
donors, 36–37
transplantation (BMT), 278–279, 477, 500
Borrelia burgdorferi, 429
Bovine spongiform encephalopathy (BSE), 430–431
Boyle, Robert, 2
Bradycardia, 53
Bradykinin (BK), 381, 388, 544
Buffy coat (BC) methods of platelet preparation, 80–1, 80f
Bystander immune hemolysis, 335
Cadaver blood, 5–6
Canadian Apheresis Study Group, 542
Canisters, 113
CAP accreditation program, 25–26
Carbohydrates, 173
Cardanus, Hieronymus, 1
Cardiac arrhythmia, 314
Cardiovascular surgery, transfusion therapy, 315–316
Caridian Spectra, 136
Catastrophic antiphospholipid syndrome (CAPS), 532
Catwright (Yt) system, 192
CD34+ cell yield in PBSC, 139f
CD44, 199
Cell lysis, 452
Cell-processing devices, 113
Cellular assays, 453
Cellular engineering
activation, 501
cell depletion
red cells, 500
T lymphocytes, 500
tumor cell purging, 500
engineered cells, clinical uses of, 492, 493t
ex vivo production of red cells, 501–502
expansion, 501
hematopoietic progenitor, 492–500, 494t, 494–5t, 499t
marrow collection, 496–497
mesenchymal stem cells (MSCs), 507
myocardial repair, 507
new blood components, development and production of, 492–493, 493t
positive selection, 501
quality assurance, 509–511
regulation of, 508–509
stem cell
collection, 497
preservation, 497–8
products, 498–500, 499t
sources of, 494–495, 495t, 496t–497t
See also under Hematopoietic stem cells
transduction, 501
umbilical cord blood banking, 502–504, 502t
Central nervous system leukostasis, 545
Central venous catheters, 536
Centrifugation instrument for cytapheresis
continuous‐flow centrifugation, 125–126
intermittent‐flow centrifugation, 123–125
Cesalpino, Andrea, 2
Cesium, 281
Chagas’ disease, 164, 428–429
Channel‐forming integral protein (CHIP), 192
Chemical modification of test red cells, 224
Chemotherapy, extensive, 280
Chido/Rogers antigens, 193
Chikungunya virus, 425, 426
Children and neonates
therapeutic apheresis for, 550
transfusion therapy in, 331–333, 370, 371
Chronic benign neutropenia, 479
Chronic granulomatous disease (CGD), 186
Chronic inflammatory demyelinating polyradiculoneuropathy, 530
Chronic lymphocytic leukemia, 546
Chronic myelogenous leukemia (CML), 9, 132, 505
Chronic renal failure, 474
Circulatory effects of transfusion, 59
Circulatory overload, 401
Circulatory system (blood), 2
Citrate toxicity, 59, 399–400
Citrate–phosphate–dextrose (CPD), 78
Citrates, 5
Civilian trauma setting, 312
Clinical Laboratories Improvement Act (CLIA) of 1998, 25
CMV‐negative blood components, 327
Coagulation factor concentrates, 83–85, 84t
inhibitors, 532
VIII, 6, 78
Coagulopathy, 114, 309–310, 381
Code of Federal Regulations (CFR), 23, 508, 564
Cohn ADL bowl, 123
Cohn, Edwin, 8, 123
Cold agglutinin disease, 532
Collagen vascular diseases, 534
Colony‐forming unit (CFU), 504
Colton (Co) blood group system, 192, 199
Community blood centers, activities of, 18–19
Compatibility testing, 216, 216t, 231–232
Complement regulatory molecules, 199–200
Complement‐dependent cytotoxicity (CDC) technique, 455
Computer crossmatch, 223
Computer‐assisted donor screening, 45
Confirmatory tests. See Laboratory testing of donated blood
Congenital immune deficiency, 285
Continuous‐flow centrifugation, 125–126
Cooley, Denton, 103
Coombs and antiglobulin serum, 6–7
Coombs test, 215, 338
Cord blood bank development, 502t
Cord blood stem cells (CBSCs), 497
Cord blood
collection and preservation, 503–504
storage conditions for, 504
cord blood collection and preservation, 503–504
red cell depletion, 504
storage conditions, 504
suitability determination, 503
written consent, 502
Cord hemoglobin, 329
Corrected count increment (CCI), 268, 271, 273
Corticosteroids, 57, 61, 132–133
Cost-effectiveness (autologous blood donation), 109–110
Creutzfeldt-Jakob disease (CJD), 46, 430–431
Critically ill patients, 477–478
Crohn's disease, 535
Cromer (Cr) system, 193
Cromer antigens, 199–200
Crossmatch, 220f, 308
abbreviated (ABO), 221–222, 321
computer, 223
full, 221
minor, 222–223
for platelet transfusion, 272–273, 319
Cryoglobulinemia, 532
Cryoprecipitate, 78–79, 254–255, 261–262
and factor VIII, 8
Cryopreservation, 497–498
Cryoprotectant, 73–74
Crystalloid and colloid solutions, 305t
Cytapheresis
complications of, 546
donation, complications and adverse reactions to, 58t
donor programs, 36
See also Apheresis
Cytomegalovirus (CMV), 165–166, 248, 423, 506
Cytomegalovirus-safe blood components. See Blood components, clinical uses of
D antigen, structure and composition of, 182–183
Decay-accelerating factor (DAF), 193
Deglycerolizing procedures, 73–74
Delayed hemolytic transfusion reaction (DHTR), 382–383, 533
Delayed hypersensitivity, 385
Dendritic cells, 494t, 505–6
Dengue virus, 427
Denis, Jean, 2
Department of Health and Human Services (HHS), 25
Dephenhydramine, 384
Dextran sulfate columns, 549
Dextran-acrylamide particles, 214
D-galactose-N-acetyl-d-galactosamine, 194
Diego (Di) system, 191–192, 197
Dimethyl sulfoxide (DMSO), 372, 498
Diphospho-glycerate (DPG), 312–313
Direct antiglobulin test (DAT), 153, 154, 212, 215, 215t
Direct T-cell allorecognition, 456
Directed donors, 115–116
Disseminated intravascular coagulation (DIC), 259, 310, 341, 381, 545
Dithiothreitol (DTT), 224
Dombrock (Do) system, 192
Dombrock glycoprotein, 200
Donated blood, sequence of testing of, 159t
Donath–Landsteiner antibody, 190
Donor arm preparation for blood collection, 50t
Donor blood, tests for, 150t
Donor laboratory testing, 503
Donor leukocyte infusion (DLI), 505
Donor leukocytes, 494t
Donor-recipient matching, 134
Doppler measurement, 233
Dose–response effect from platelet transfusion, 268
Duffy antigen receptor for chemokines (DARC), 186
Duffy system, 186–187
Ebola virus, 432
Education of donors, 29
Elective surgery, 17
Electrolyte and acid-base imbalance, 400
Electrolytes, 314
Electromechanical pumps, 369
Elliott, John, 7
Elution techniques, 226
Embolism, 401
Employment of blood donors, 30
Endoplasmic reticulum (ER), 451
Engineered cells, clinical uses of, 492, 493t
Enteroviruses, 200
Enzymatic activity, 200
Enzymatic cleavage of ABO, 89–90
Enzyme immunosorbent assay (EIA), 160, 165
Enzyme-linked immunosorbent assay (ELISA), 455
Enzymes, 213
and enhancement media, 224
Epinephrine, 394
Epstein-Barr virus (EBV), 425, 506–507
lymphoproliferative disorders, 506–507
Errors in transfusion medicine. See Blood banking and transfusion medicine
Erythrocytapheresis, 544
Erythropoietin (EPO), 103
therapy, guidelines for, 476t
use of, 109
See also Hematopoietic growth factors
Evidence-based guidelines for transfusion, 101
Exchange transfusion, 329–31, 330t
complications of, 330t
Extracorporeal photochemotherapy, 546–548
See also photopheresis
Extravascular hemolysis, 211
Factor IX, deficiency of, 262
Factor VII, activated, 312
Factor VIII, 8
deficiency of, 259–260
Familial hypercholesterolemia, 548–549
Family history of donation, 33
Fantus, Bernard, 5
Fatalities, transfusion-related, 361t
FcRIIb, 205
Febrile nonhemolytic transfusion reaction (FNHTR), 384–385, 388, 465
Federation of Red Cross and Red Crescent Societies, 22
Fenwal CS-3000, 126
Fetus, 285
Fibrin sealant, 255
composition of, 256t
indications for, 257t
Fibrinogen, 85, 261
Filters, 81, 82
Filtration leukapheresis (FL), 133
Filtration, 75, 76
First transfusions, blood (in US), 4
Fisher–Race system, 182, 183t
Flaviviridae, 425
Fluosol, 91
Food and Drug Administration (FDA), US, 19, 20, 23–24, 219, 508
Fractionation process (plasma), 19
Fresenius Kabi
Alyx, 127
Amicus, 126–127
AS, 104 129
Fresh frozen plasma (FFP), 8, 72, 77–8, 87–88, 252, 253, 253t, 257–258
Frozen deglycerolized red blood cells, 73–74, 250
24-hour Frozen plasma (FP-24), 77, 252, 253
thawing, 77–78
Full crossmatch, 221
Fulminant hepatitis, 419
Fya gene, 186
Gambro (COBE/Caridian) blood cell separator models, 126
Gamma irradiation, 282
G-CSF, 61, 137t
Gel test, 214
Gender of donors, 28–29
Gerlich (Ge) system, 193
GIL antigen, 194
Global Blood Safety unit, 22
Glomerulonephritis, rapidly progressive, 531
Glucose content, 330
Glucose–citrate mixtures, 7
Glue, fibrin, 255
Glycoporphins, 193, 197
Glycosylphosphatidylinositol linkage, 193
Good manufacturing practices (GMPs), 509–511, 562t, 564
Goodpasture’s syndrome, 530
Graft survival, alteration of, 396–397
Graft-versus-host disease (GVHD), 249, 280–281, 456
pathogen inactivation and prevention of, 283–284
prevention of, 283
transfusion associated, 396t
bone marrow transplant associated, 396t
Graft-versus-leukemia (GVL) effect, 456
Granulocyte colony-stimulating factor (G-CSF), 132–133, 276
See also Hematopoietic growth factors
Granulocyte concentrate production, 131–132
donor-recipient matching, 134
filtration leukapheresis (FL), 133
function obtained by leukapheresis, 133
granulocyte colony stimulating factor (G-CSF), 132–133
hydroxyethyl starch in leukapheresis, 132
storage for transfusion, 133–134
Granulocyte, 82, 131–132, 204–206, 205t
alloantigens, 205t
anaplasmosis, 429
compatibility, 236
donors, 57
mobilization in normal donors, 484
transfusion, 9, 286, 275–276, 329, 389, 465–466
Granulocyte-specific antigens, 205t
Guidelines, adherence to, 102
Guillain-Barré syndrome, 522–529
Guillain-Barré disease, 537
GVHD, transfusion-associated, 395–396, 396t
Haemonetics instruments, 128–129, 128f
Haemonetics system, 125, 126
Multiple Component System (MCS), 129
Hageman factor, 381
Haplotypes, HLA, 447–448, 447f
Haptoglobin, 387
Harvey, William, 2
Health professional education program, 102
HemAssist, 91
Hematologic diseases, 531, 532
cold agglutinin disease, 532
cryoglobulinemia, 532
thrombotic thrombocytopenic purpura (TTP), 531–532
Hematologic malignancies, 284
Hematoma, 55, 60
Hematopoietic cell transplantation (HCT), 58
See also Transfusion therapy, and bone marrow
Hematopoietic growth factors, 475t
erythropoietin (EPO)
acquired immune deficiency syndrome (AIDS), 476–477
anemia of chronic disease, 475–476
anemia of prematurity, 477
autologous blood donors, 477
bone marrow transplantation, 477
chronic renal failure, 474
complications of, 478
critically ill patients, 477–478
description and pharmacology, 474, 476t
perioperative situations, 477
granulocyte colony-stimulating factor (G-CSF)
AIDS, 480
aplastic anemia, 480
description and pharmacology, 478, 479t
granulocyte mobilization in normal donors, 484
neutropenia due to marrow suppression, 478–479
stem cell mobilization in normal donors, 480–4, 481f, 482t, 483f
second generation thrombopoietic growth factors, 485–6
thrombopoietin
description and pharmacology, 484–5
due to marrow suppression, 485
megakaryopoiesis, stimulation of, 485
in vitro uses of, 486
Hematopoietic progenitor cells (HPCs), 37, 492–500, 494t, 494–5t, 499t
Hematopoietic stem cell preservation
cryopreservation, 497–498
liquid preservation, 497
Hematopoietic stem cell products,
371–373, 372t
bone marrow, 496–497,
498–9, 499t
peripheral blood stem cells, 499
umbilical cord blood (UCB), 499–500
Hematopoietic stem cell transfusion,
262, 263t, 372t
Hematopoietic stem cells, 496
Hemochromatosis patients as blood donors, 47
Hemoglobin testing, 48
Hemoglobin, 90
function, 312–313
Hemoglobinopathies. See Transfusion therapy
Hemolink, 91
Hemolysis, 371
mechanical, 60
Hemolytic anemia, 429
Hemolytic disease of newborn (HDN), 6, 181, 329
at-risk fetus, monitoring of,
233–234, 234t
HDN-Rh globulin prevention,
234–235
laboratory investigation, 232–233
Rh typing, 235
prevention, 234–235
See also Laboratory detection of blood groups
Hemolytic transfusion reactions,
380–382, 380t, 382f, 382t
signs and symptoms of, 392t
Hemophilia
A (factor VIII deficiency), 337, 337t
B (factor IX deficiency), 337
Hemopure, 91
Hemorrhage, 4
Hepatitis A virus (HAV), 166, 415
Hepatitis B core antibody (anti-HBc), 161, 417
Hepatitis B virus (HBV), 415–417, 416f
Hepatitis B, NAT for, 161
Hepatitis C antibody (anti-HCV), 161
Hepatitis C virus (HCV), 418
Hepatitis E virus (HEV), 419
Hepatitis G, 418–419
Hepatitis tests. See Laboratory testing of donated blood
Hepatitis, surrogate testing for,
161–162
Hereditary hemochromatosis (HHC), 47, 467
Heterodimers, 451
Heterophil-positive mononucleosis, 425
Histamine, 385
History, 1–10
ancient times, 1
anticoagulation, 4–5
apheresis, 9
blood banking/banks, 5
blood groups, discovery of, 4
cadaver blood, 5–6
coombs and antiglobulin serum,
6–7
cryoprecipitate and factor VIII, 8
first transfusions (in US), 4
granulocyte transfusions, 9
leukocyte antigens and antibodies,
8–9
plasma, 7
plastic bags and blood components,
7–8
platelet collection/storage/ transfusion, 9
red cell preservation, 8
Rh blood group system, 6
Rh immunization, prevention of, 6
time period
1500–1700, 1–3
1800s, 3
World War II, 7
HIV. See Human immunodeficiency virus (HIV)
HLA. See Human leukocyte antigens (HLA)
Hospital blood bank operations,
571–572, 571t
Hospital Laboratory Accreditation Program (HLAP), 25–26
Human herpesvirus 6 (HHV-6)/
Human herpesvirus 8 (HHV-8), 426
Human immunodeficiency virus (HIV)
antibody tests, 421
antigen testing, 159–160, 421
infection and AIDS (See under
Transfusion-transmitted
diseases)
laboratory screening tests, 420
testing, 158
Human leukocyte antigen (HLA)
matching, 286–287
for platelet transfusion, 271–272,
272f
Human leukocyte antigen (HLA)
system in transfusion medicine
clinical HLA testing for
transplantation
cellular assays, 453
HLA antibody screening, 455
lymphocyte crossmatch, 455
molecular typing of HLA alleles,
453–455, 453t
serologic typing of HLA antigens,
452–453
genomic organization of
human MHC, 446–447
HLA haplotypes, 447–448, 447f
human minor histocompatibility
antigens, 456
immunologic role of (peptide
presentation), 450–452
structure and polymorphism of,
448–450, 449f
tissue expression of, 448
in transfusion therapy
Febrile nonhemolytic transfusion
reaction (FNHTR), 465
granulocyte transfusion, 465–466
HLA alloimmunization, 461
HLA-disease association, 467
neonatal alloimmune
thrombocytopenia (NAIT),
466–467
parentage HLA testing, 468
refractoriness to platelet
transfusion, 462–463
transfusion-associated graft-
versus-host disease (TA-
GVHD), 463–465
transfusion-related acute lung
injury (TRALI), 466
in transplantation, 456–457
allogeneic hematopoietic stem
cell transplantation,
459–460
solid organ transplantation,
457–459
Human leukocyte antigen (HLA), 8,
18, 166
Human minor histocompatibility
antigens, 456
Human platelet alloantigens,
202–203t
Human T-lymphotrophic virus
(HTLV), 160, 423–424
Human transfusion, 3
Hydroxyethyl starch (HES), 57, 61, 82,
132, 304, 539
in leukapheresis, 132
Hyperacute rejection, 457, 458
Hyperhemolysis, 335
Hypersensitivity, passive transfer of,
401
Hypertension, 61
Hyperviscosity syndrome, 532
Hypocalcemia, 313
Hypofibrinogenemia, 261
Hypo-proliferative thrombocytopenia,
263
Hypotension, 394
Hypotensive reactions, 388
Hypothermia, 313, 399
Identity theory, 30
Idiopathic thrombocytopenic purpura,
AIDS-related, 535
IgA deficiency.
screening donors for, 167
See also Transfusion therapy
IgM antibodies, 226
Ii blood group antigens, 194–195
Immune cytopenias, 322
Immune serum globulin, 85–87
Immune system, 252
Immunization, 181
after blood transfusion, 394t
to blood group antigens, 394, 394t
Immunotherapy, 506, 507
In vivo red cell compatibility testing,
231–232
Incentives, role of, 34
Incompatible crossmatch, patient with, 230–232
Indian (In) system, 193–194
Infusion pumps, 369
Infusion solutions, 365
Inspection and Accreditation (I&A) program, 25
Integral plastic bag system, 71f
Integrated model (blood donation), 30–31
Intensive care units (ICU), 477
Intermittent-flow centrifugation, 123–125
Internal quality audits, 568
International normalized ratio (INR), 253
International Organization for Standardization (ISO), 563t, 564
International Society for Blood Transfusion (ISBT), 22–3
Intracellular adhesion molecule (ICAM), 191
Intraoperative blood salvage. See Autologous blood donation and transfusion
Intravenous immune globulin (IVIG), 41, 86–87, 342–344, 466, 529, 533, 535
Intravenous infusion sets, 363
Investigational device exemptions (IDEs), 509
Investigational new drug (IND), 493t
Iron overload, 401
Irradiated blood components, 328
acquired immune deficiency syndrome, 285–286
allogeneic bone marrow transplantation, 284
aplastic anemia, 285
autologous bone marrow transplantation, 284
congenital immune deficiency, 285
fetus, 285
granulocyte transfusions, 286
hematologic malignancies, 284
HLA matching, 286–287
neonates, 285
noncellular blood components, 286
solid tumors, 285
See also Blood components, clinical uses of
Irradiation of blood components, 82, 281–282
quality control of, 283
storage, 282–283
See also Plasma derivatives
John Milton Hagen (JMH), 194
Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 574
Kell glycoprotein, 200
Kell system, 185–186
Kidd system, 187
Kidney transplantation, 277–278, 322–323
Knops (Kn) system, 193
Labeling, 49
errors, 361
systems, 223–224
Laboratory detection of blood groups
direct antiglobulin test (DAT), 215, 215t
hemolytic disease of newborn (HDN), 232–235
at-risk fetus, monitoring of, 233–234, 234t
HDN-Rh globulin prevention, 234–235
laboratory investigation, 232–233
Rh typing, 235
immunologic mechanisms of red cell destruction, 210–211
incompatible crossmatch, patient with, 230–232
in vivo red cell compatibility testing, 231–232
phagocytosis related assays, 232
red cell antibody-antigen reaction agglutination, 211
antigen–antibody reaction enhancement, 212–213
detection tests, 214–215
red cell antibody identification, 224–226, 225f
absorption, 226
Laboratory detection of blood groups
.direct antiglobulin test (DAT) (cont’d)
chemical modification of test red cells, 224
elution, 226
enzymes and enhancement media, 224
neutralizing/inhibitor substances, 226
sulfhydryl reagents, 226
red cell availability for transfusion
blood availability, 226–228, 227t, 230
crossmatch, emergency, 229
surgical blood ordering (standard/maximum), 228
type and screen, 228–229
uncrossmatched red cells, 229–230
red cell compatibility testing,
216–217, 216t, 217t
ABO and Rh typing, 218–219, 219t
crossmatch, 221–223
identification of recipient and blood sample, 217
labeling systems, 223–224
screening test, 219–220, 221t
transfusion service record review, 217–218
Laboratory quality controls, 569
Laboratory testing of donated blood
ALT, use of, 161–162
autologous, 108
bacterial detection, 164–165
Chagas’ disease, 164
confirmatory tests, 158–159, 159t
donor blood, tests for, 150t
hepatitis tests
hepatitis B core antibody (anti-HBc), 161
hepatitis B surface antigen (HBsAg), 160
hepatitis C antibody (anti-HCV), 161
NAT for hepatitis B, 161
human T-cell lymphotrophic virus, 160
optional tests for donor blood
Babesia microti, 165
cytomegalovirus (CMV), 165–166
HLA/Granulocyte antibody detection in donors, 166
parvovirus and hepatitis A virus, 166
platelet-specific antibodies and antigens, 166
red cell antigen, 166
screening donors for IgA deficiency, 167
red cell blood group testing
ABO typing, 149–151, 151t, 152t
positive direct antiglobulin tests in normal donors, 154–155
red blood cell antibody detection, 153–154
Rh typing, 151–152
surrogate testing for hepatitis, 161–162
syphilis testing of donated blood, 163
transmissible diseases, testing for concepts of, 155
HIV testing, 158
in resource limited settings, 155–156
results of, 162
viral testing, 156–158
window phase, 158, 159–160
West Nile virus (WNV) infection, 163–164
Lactate dehydrogenase (LDH), 531
Lambert-Eaton syndrome, 530
Landsteiner, 4
Latex agglutination test, 165
Latham bowl, 123, 126, 128f
Latham, Allan, 123
Latham, Jack, 9
Leacock, John, 3
Leishmaniasis, 430, 431
Leukapheresis, 125
complications in, 61
donors, 57
See also Apheresis, component production by Leukoagglutination, 134
Leukocyte-depleted red cells, 247–249, 248t
Leukocyte depletion, 283
filters, 76–77
248t, 249, 250, 252, 363
history of, 75–76, 76t
Leukocyte-reduced red blood cells, 75–77, 76t
definition of component, 75
leukocyte depletion filters, 76–77
leukodepletion, history of, 75–76, 76t
Leukocytes, 8–9
antibodies, 8–9, 386
antigens, 8–9
in blood components, adverse effects of, 76t, 378t
Leukodepletion,
Leukopenia, 341
Lewis system, 190–191
Libavius, Andreas, 1–2
Licensure, 24, 25, 68t
Lipids, 173
Liquid preservation, 497
lookback, objectives of, 162–163
Lower, Richard, 2
Low-ionic-strength solution (LISS), 213
Lupus anticoagulant, 341
Lutheran antigen, 188, 197
Lutheran system, 188
LW system, 191
Lyme disease, 429
Lymphocytapheresis, 134–135
Lymphocyte crossmatch, 455
Lymphocyte depletion, 60–61
Lymphocytotoxicity, 134
Lymphoplasmapheresis, 534
Lymphoproliferative disease, 506
Major histocompatibility complex (MHC), 505
Malaria, 428
Massive transfusions, 308–309, 309t
coagulopathy in, 309–310
Mauroy, Antoine, 2–3
McLeod phenotype, 186
Mechanical barrier system, 362
Mechanical hemolysis, 60
Medical Event Reporting System for Transfusion Medicine (MERS-TM), 570
Medical history of whole blood donors, 43–47, 44–45t
Medications, 365
Medico-Chirurgical Society of London, 3
Megakaryocyte growth and development factor (MGDF), 485
Megakaryopoiesis, stimulation of, 485
Mendelian inheritance of HLA haplotypes, 448f
Mesenchymal stem cells (MSCs), 507
Microaggregates, 313–314
Microbial receptor, 200
Microchimerism, 399
Microhematocrit, 48
Middle cerebral artery (MCA), 233
Military trauma center, 311
Minimal donor exposure programs, 116–117
Minor crossmatch, 222–223
Minor histocompatibility antigen, 456
Mixed lymphocyte culture (MLC), 274
MNSs system, 188–189
Molecular typing of HLA alleles, 453–455, 453t
Molecules, function of. See Blood groups
Monoclonal gamopathies, 530
Monocyte monolayer assay (MMA), 232
Mononuclear cell apheresis, complications in, 62
Mononuclear cell collection, lymphocytapheresis for, 134–135
Mortality risk scores, 458
Mortality, overall, 398–399
Multiple coagulation factors, deficiency of, 255–259
disseminated intravascular coagulation, 259
massive transfusion, 258–159
prothrombin-complex deficiency, 257–258, 258f
Multiple Component System (MCS), 129
Multiple myeloma, 531
Multiple sclerosis, 529
Murine myeloproliferative leukemia virus, 484
Myasthenia gravis, 529
*Mycoplasma pneumoniae* infection, 195
Myelogenous leukemias, 545
Myeloid recombinant growth factor therapy, 478, 479t
Myocardial repair, 507
Nageotte chamber, 77
NAT. See Nucleic acid amplification testing (NAT)
National Academy of Sciences, 281, 433
National Blood Foundation, 21
National Cancer Institute (NCI), 9, 125
National Institutes of Health (NIH), 9, 244, 417
National Marrow Donor Program (NMDP), 36, 459–460, 497
Natural killer (NK) cells, 451–2, 505
NCI-IBM Blood Cell Separator, 125
Neonatal alloimmune neutropenia, 344–345
Neonatal alloimmune thrombocytopenia (NAIT), 343–344, 466–467
Neonates, 277, 285
transfusion for, 325–331, 370–371
Nerve injuries, 54
Neurologic diseases, 522
Neuromyelitis optica, 530
Neutropenia
chronic benign, 479
due to marrow suppression, 478–479
neonatal alloimmune, 344–345
Neutrophils, 204–205, 387
Nitric oxide, 243
Noncellular blood components, 286
Nongovernmental blood bank organizations. See Blood supply
Nonhospital setting, transfusion in, 373
Nonimmunologic complications of blood transfusion. See Transfusion, complications of Nonimmunologic hemolysis, 384
Noninfectious serious hazards of transfusion (NISHOT), 377
Nucleic acid amplification testing (NAT), 160, 163–164, 417, 421
for hepatitis B, 161
Nursing care of patients, 369–370
Octaplas, 87, 88t
OK system, 194
Opponent process theory, 30
Optional tests for donor blood. See Laboratory testing of donated blood
Organ preservation, 458
Organizational influences on blood donation, 33–34
Osmotic hemolysis, 73
Outpatient transfusions, 19
Oxalic acid, 5
P system, 189–190
Packed red blood cells (PRBCs), 72, 311
Panel reactive antibody (PRA), 455
Parasitic diseases, 427–429
Chagas' disease, 428–9
malaria, 428
Parentage HLA testing, 468
Paroxysmal cold hemoglobinuria, 190
Paroxysmal nocturnal hemoglobinuria (PNH), 200, 324–325
Parvovirus, 424–425
and hepatitis A virus, 166
Passenger lymphocyte-related hemolysis, 383–4
Passenger lymphocytes, 324
Passive transfer of hypersensitivity, 401
Pasteurization, 83
Pathogen inactivation techniques, 87–89, 274
Pathogen-inactivated blood components. See Blood components
Patient blood management (PBM), 100–101, 101t
acute normovolemic hemodilution, 110–112, 112t
allogeneic transfusion, 103, 106
blood use monitoring, 102
directed-donor blood, 115–116
donors, 477
evidence-based guidelines for transfusion, 101
guidelines, adherence to, 102
hemostatic agents minimizing transfusion, 115
intraoperative blood salvage
blood salvage, development of, 112–113
devices used for, 113–114, 113t
limiting blood loss for laboratory testing, 115
minimal donor exposure programs, 116–117
ordering practices, 573
patient-specific donation, 116
physician and health professional education program, 102
postoperative blood salvage, 114–115
preoperative anemia detection and management, 102–103
preoperative autologous donor blood, 103–106, 104t
adverse reactions to, 107–108
blood donation by infectious patient, 108–109
collection processing, 107
complications of transfusion, 110, 110t
cost-effectiveness, 109–10
erythropoietin, use of, 109
indications for transfusion, 109
laboratory testing, 108
medical requirements, 106–107, 106t
storage of blood, 107
Patient-specific blood donation, 116
PBSC. See Peripheral blood stem cells (PBSC)
Pediatric patients, transfusion therapy in, 331–333
Pegelius, Magnus, 1
Pemphigus, 535
Peptide presentation, 450–452
Percutaneous mechanical thrombectomy, 384
Percutaneous umbilical cord blood sampling (PUBS), 233
Perfluorocarbon, 90, 91
Peripheral blood lymphocytes (PBLs), 451–2
Peripheral blood mononuclear cells, 505
Peripheral blood platelet counts, 483f
Peripheral blood stem cells (PBSC), 62, 497, 499
collection on normal donors, effects, 137
collection procedures, 136–137
concentrates, characteristics of, 137–138, 137t, 138t
donor selection, 140
plasmapheresis and source plasma, 140–141
quality control of, 138–139, 138t, 139f
quantity of cells in, 138t
storage of, 139–140
Pertussis, malignant, 535
Phagocytosis, 133
related assays, 232
Philosophical Transactions of Royal Society, 2
Phlebotomists, 50t, 51
Phosphate-dextrose (CPD), 503
Phosphatidylinositol, 173, 178f
Phosphatidyl-inositol-glycan (PIG), 205
Photometers, 154
Photopheresis, 546–548, 547t
Phylogenetic analysis, 179
Physical examination of blood donor, 47–49
Physician education program, 102
Physiology in red cell transfusion decisions, 242–244, 243t
Plasma Protein Therapeutics Association (PPTA), 22
Plasma, 78, 252
and blood program, 7
collection activity, 20
collection system (See Blood supply)
definitions of, 19
derivatives (See also Blood components)
coagulation factor concentrates, 83–85, 84t
fibrinogen, 85
immune serum globulin, 85–87
exchange (See Therapeutic apheresis)
histamine, 385
protein depletion, 61
production for transfusion, 18
Plasmapheresis, 19
complications, 61
donors, 57–58
and source plasma, 140–141
Plasmodium falciparum, 193, 428
Index

Plasmodium knowlesi, 187
Plasmodium vivax, 187
Plastic bags, 9
and blood components, 7–8
Plasticizers, 314
Platelet collection/storage/transfusion, 9
Platelet transfusion, 262–274, 263t
active bleeding, treatment, 265–268, 266f, 267f
outcome, 268–71
ABO and Rh in, 268–270
patient factors, 270, 271t
platelet concentrate factors, 271
prevention of bleeding
(prophylaxis), 263–265, 264f
indications for transfusion, 264
platelet dose, 264–265
prophylaxis for invasive procedures, 268
Platelet transfusion refractoriness, 270
management strategies, 271–274
alloimmunization prevention, 274
crossmatching, 272–273, 273t
HLA matching, 271–272, 272f
other approaches, 273
platelet concentration volume,
reduction of, 274
outcome, 270
Plateletpheresis, 129–130, 131, 262
Platelet-rich plasma (PRP) method,
80, 80f
Platelets, 88–89, 200–204, 202–203t, 204t
additive solutions, 79t
apheresis, 262
compatibility, 235–236
concentrate, 79–82, 79t, 80f, 274
crossmatching, 272, 273
depletion, 57
depletion/damage, 60
function and storage of, 130
production, 17
refractoriness prevention, 274
refractory patient, 273, 273t
transfusion, 9, 262–274, 328, 341, 388
Pluripotent hematopoietic stem cells,
499
Poliovirus, 200
Polybrene, 213
Polyethylene glycol (PEG), 213
Polyheme, 91
Polymerase chain reaction
(PCR), 454
Polypeptides, 177
Pool, Judith, 8
Positive direct antiglobulin tests,
154–155
Postdonation care, 52
Postoperative blood salvage,
114–115
Postpartum hemorrhage, 3
Postperfusion syndrome, 425
Posttransfusion purpura (PTP), 533
Pregnancy, 334
Pregnant women, 277
transfusion therapy, 340
Preoperative autologous donor blood,
103–106, 104t
adverse reactions to, 107–108
blood donation by infectious
patient, 108–109
cardiovascular conditions,
106, 106t
collection processing, 107
complications of transfusion, 110,
110t
cost-effectiveness, 109–10
erythropoietin, use of, 109
indications for transfusion, 109
laboratory testing, 108
medical requirements, 106–107,
106t
storage of blood, 107
Preservative solutions, anticoagulant, 8
Prestorage leukodepletion, 76
Pretransfusion testing, 326
Process analysis and management
(PAM), 561
Procoagulant activity, 381
Progenitor cells, 82–83, 494t
Prophylaxis,
invasive procedures, 268
platelet transfusion, 268
Prothrombin-complex deficiency,
257–258, 258f
Pseudomonas, 389
Psoralen, 88
Psychosocial theories (to blood donor
motivation), 30
Push-pull technique, 334
Quality assurance
in blood supply system, 564–569
leadership, 565
in patient therapy (See Blood
banking and transfusion
medicine)
systems, 560–564, 561t, 562t, 563t, 564t
in transfusion service, 570–574
Quality systems in blood supply. See
Blood banking and transfusion
medicine
Quality
hierarchy, 564t
principles (by AABB), 562t
in transfusion therapy, 570–571
Quinton–Mahurkar catheters, 536
Race/ethnicity of donors, 29
Radiation dose, 281–282
Radioimmunoblot assay (RIBA), 158
RAPH system, 194
Rare blood types, 197t, 345–346
RBC membrane proteins, 178f
Reagent red cells used for antibody
identification, 225f
Receptors and adhesion molecules,
198–199
Recurrent spontaneous abortions, 507
Red blood cell components, use of,
246–250
Red blood cell transfusion, effects of,
251–252
circulation, 251
hemoglobin concentration, 251
immune system, 252
red cell production, 252
transfused red blood cells, survival
of, 252
see also blood components, clinical
uses of
Red blood cells, 72–73, 72t
antibody detection, 153–154
component, description of, 73–74
frozen/deglycerolized, 73–75
leukocyte-reduced, 75–77, 76t (See
Leukocyte-reduced red blood
cells)
storage conditions/duration, 72t, 73
transfusions, 325–326
transfusion trigger, 244–245
washed red cells, 75
Red cell antibody characterizing, 196t
identification See Laboratory
detection of blood groups
Red cell antibody-antigen reaction,
detection
affinity column, 215
gel test, 214
slide/tiletest, 214
solid-phase tests, 214
tube tests, 214
See also Laboratory detection of
blood groups
Red cell antigen, 166
alteration, 198t
antibodies to, 195–196, 196t
Red cell aplasia, 533
Red cell availability for transfusion.
See Laboratory detection of
blood groups
Red cell blood groups. See Blood
groups testing; Laboratory
testing of donated blood
Red cells, 89
alloantibodies, 336
in AS-1 (Adsol), 70t
clinical uses of, 246
see also blood components, clinical
uses of
collection, 130–131, 131t
compatibility testing See Laboratory
detection of blood groups
depletion, 504, 544
destruction, immunologic
mechanisms of, 210–211
exchange, 544
function, 198, 199t
hemolysis, causes of, 380t
preservation, 8
products used, 326–327
structure, 197–198, 198t
universal, 89–90
washed, 75, 249–50
Refractoriness to platelet transfusion,
462–463
management strategies, 271–274
alloimmunization prevention,
274
crossmatching, 272–273, 273t
HLA matching, 271–272, 272f
other approaches, 273
outcome, 270
Registration of blood donors, 42–43
Renal diseases
  glomerulonephritis, rapidly progressive, 531
  Goodpasture's syndrome, 530
  multiple myeloma, 531
Repeat identification of red cell antibodies, 217t
Respiratory problems, 394
Restriction fragment length polymorphism (RFLP), 453
Rh antigen, 89–90
  blood group system, 6
  immunization, prevention of, 6
  system See Blood groups
  type, 151–152, 235–236
  RHCE, 182
Rheumatoid arthritis, 534
Rh immune globulin (RhIG), 235
Rh-incompatible transplants, 319–322, 320f, 320t
Rh-mismatched transplants, 321
Rh-null individuals, 184
Riboflavin, 87–88
Robertson, Oswald, 5
Rocky mountain spotted fever (RMSF), 430
Rogers (Rg) and chido (Ch) system, 193
Roller pumps, 369
Rous, Peyton, 69
Safe blood, strategies of, 42t
Scianna (Sc) system, 192
Scleroderma, 534
Screening test, 219–220, 221t
Sedimentation, 72
Seizures, 54
Semiautomated apheresis methods, 122
SEN virus, 419
Sepsis, 390t, 535
  neonatal, 329
Sequence-based typing, 454
Sequence-specific oligonucleotide probe (SSOP) methods, 454
Sera testing, 344
Serial donations, complications of leukapheresis donors, 57
  plasmapheresis donors, 57–58
  platelet depletion, 57
Serologic typing of HLA antigens, 452–453
Serum chemistries, 482t
Severe combined immune deficiency (congenital), 279–280
Sickle cell disease (SCD), 329, 333–336, 333t
  components, 336
  red cell antibodies, 334–335
  transfusion, clinical indications for, 333–334, 333t
  transfusion reactions, 335
Simian foamy virus (SFV), 427
Single coagulation factors, deficiency of, 259–262
  factor IX, deficiency of, 260–261
  factor VIII, deficiency of, 262
  fibrinogen, 261
  hypofibrinogenemia, 261
  von Willebrand's disease, 261–262
Single-donor platelet concentrate production, 129–130
Single-use reservoirs, 113
Slide/tile typing, 214
Social influences on blood donation, 32–33
Socioeconomic characteristics, 29
Solvent-detergent plasma, 87, 88t, 254
Solvent-detergent (SD) process, 84, 254
Source plasma, 19, 140–141
Southern blotting analysis, 453
Spontaneous bleeding, 267
Standard operating procedures (SOPs), 561
Staphylococcal protein A (SPA) columns, 549–550
Staphylococcus epidermidis, 389
Stem cell
  mobilization in normal donors, 480–484, 481f, 482t, 483f
  sources of, 492–3, 494t
  transplantation, transfusion in, 461
  See also Cellular engineering, hematopoietic stem cells, and progenitor cells
Sterile connector devices, 116–117
Stored red blood cells, clinical effects of, 246
Sulfhydryl reagents, 226
Surgical blood ordering (standard/maximum), 228
Surrogate testing, 417–418
for hepatitis, 161–162
Syphilis, 412–413
testing of donated blood, 163
Systemic lupus erythematosis (SLE), 534

T-activation, 328
T lymphocytes, 500
Taq polymerase, 454
TEG/ROTEM, 310, 310f, 310t
Terumo Trima Accel™, 127–128
Thalassemia, 335
Thawing, 77–78, 498
Theory of planned behavior (TPB) on blood donation, 31
Theory of reasoned action, 30
Therapeutic apheresis
in children, 550
photopheresis, 546–548, 547t
plasma exchange therapy
apheresis procedure, 543–544
biochemical changes, 539–540, 540f, 541f
complications of, 541–544, 542t
red cell depletion, 544
replacement solutions, 538–539, 538t, 543
techniques of, 536–537, 537f
vascular access for plasma exchange, 535–536, 542–543
plasma exchange therapy, clinical uses of, 521–522, 522t, 523t–528t
alloimmune platelet refractoriness, 533
amyotrophic lateral sclerosis (ALS), 530
autoimmune hemolytic anemia, 533
autoimmune thrombocytopenia, 533
catastrophic antiphospholipid syndrome, 532
chronic inflammatory demyelinating polyradiculoneuropathy, 530
cogulation factor inhibitors, 532
collagen vascular diseases, 534
delayed hemolytic transfusion reaction, 533
Guillain-Barre syndrome, 522–529
hematologic diseases, 531–532
hyperviscosity syndrome, 532
idiopathic thrombocytopenic purpura, AIDS-related, 535
infectious and inflammatory diseases, 535
Lambert–Eaton syndrome, 530
monoclonal gamopathies, 530
multiple sclerosis, 529
myasthenia gravis, 529
neurologic diseases, 522
neuromyelitis optica, 530
pemphigus, 535
posttransfusion purpura (PTP), 533
red cell aplasia, 533
renal diseases, 530–531
rheumatoid arthritis, 534
scleroderma, 534
solid organ transplantation, 533–534
systemic lupus erythematosus (SLE), 534
Wilson's disease, 535
red cell exchange/erythrocytapheresis, 544
selective adsorption columns, use of dextran sulfate columns, 549
familial hypercholesterolemia, 548–549
staphylococcal protein A (SPA) columns, 549–550
therapeutic cytapheresis, 544–546
complications of, 546
myelogenous leukemias, 545–546
thrombocytosis, 546
Therapeutic bleeding, 55
Therapeutic cytapheresis, 544–546
complications of, 546
myelogenous leukemias, 545–546
thrombocytosis, 546
Therapeutic plasma exchange (TPE), use of, 522t
See also Therapeutic apheresis

Thrombocytopenia, 9, 262, 309, 341
neonatal alloimmune, 343–344

Thrombocytosis, 546

Thromboelastogram measures, 315

Thrombopoietic growth factors, second generation, 485–6

Thrombopoietin (TPO), 484–5
See also Hematopoietic growth factors

Thrombosis, 55

Thrombotic thrombocytopenic purpura (TTP), 531–532

Tick-borne diseases, 429–430
babesiosis, 429
granulocytic anaplasmosis, 429
lyme disease, 429
rocky mountain spotted fever (RMSF), 430

Toscana virus, 426

Total process control, 561

Toxoplasmosis, 431

Transcription errors, 158

Transfusion committee, 574

Transfusion medicine errors in, 569–570, 572
quality program, 570t

Transfusion Safety Officer, 100, 102

Transfusion service record review, 217–218

Transfusion therapy
acute blood loss
acid-base balance, 313
activated factor VII, 312
blood bank procedures, 306–307
blood samples for laboratory tests, 314
blood types, changing, 307–308, 307t
coagulopathy, 309–310
electrolytes, 314
hemoglobin function, 312–313
hypocalcemia, 313
hypothermia, 313
massive transfusion, 308–309, 309t
microaggregates, 313–314
physiology and therapy, 304–306, 305t
plasticizers, 314
TEG/ROTEM, 310, 310f, 310t
trauma, 311–12

AIDS
anemia, 340–1
disseminated intravascular coagulopathy, 341
leukopenia, 341
lupus anticoagulant, 341
thrombocytopenia, 341
autoimmune hemolytic anemia (AIHA), 339t
decision to transfusion, 338–340
autoimmune neutropenia (AIN), 345
autoimmune thrombocytopenia, 342–343
cardiocerebral surgery, 314–316
stored red blood cells in, 316
hematopoietic cell transplantation (HCT), 316–318, 317t
ABO- and Rh-incompatible transplants, 319–322, 320f, 320t
immune cytopenias, 322
posttransplantation, 318–319
posttransplant chimeric states, 322
pretransplant, 318
in hemoglobinopathies
sickle cell disease, 333–336, 333t
thalassemia, 335
hemophilia, 337, 337t
with IgA deficiency, 341–342
neonatal alloimmune neutropenia, 344–345
neonatal alloimmune thrombocytopenia, 343–344
neonates, 325–331
administration devices, 327
CMV-negative blood components, 327
exchange transfusion, 329–331, 331t
granulocyte transfusions, 329
irradiated blood components, 328
platelet transfusions, 328
pretransfusion testing, 326
red blood cell transfusions, 325–326
red cell products used, 326–327
T-activation, 328
paroxysmal nocturnal hemoglobinuria (PNH) patients, 324–326
pediatric patients transfusion techniques, 331–333
pregnant women, 340
rare blood types, 345–346
solid organ transplantation, 322–324, 533–534
von Willebrand's disease, 337–338

Transfusion
on AIDS, effect of, 422
committee, 574
massive, 258–259, 308–309, 309t
coagulopathy in, 309–310
Transfusion, complications of,
377–379, 378t, 379t, 380t
acute lung injury (ALI), 385–387, 386t
allergic reactions, 385
anaphylactic reactions, 387
bacterial contamination
transfusion-transmitted, 389–391, 390t
delayed hemolytic transfusion reaction (DHTTR), 382–383
febrile nonhemolytic transfusion
(FNHT) reactions, 384–385
granulocyte transfusions, 388–389
hypotensive reactions, 388
in immune modulation
GVHD, transfusion-associated, 395–396, 396t
immunization to blood group antigens, 394, 394t
transfusion-related, 396
immunological complications of
transfusion
graft survival, alteration of, 396–397
long-term mortality, 398–399
microchimerism, 399
susceptibility to infection, increased, 398
susceptibility to recurrence of
cancer, increased, 397–398
immunologic complications of
hemolytic transfusion reactions, 380–384, 380t, 382f, 382t
management of, 392, 393t
nonimmunologic complications of
bleeding tendency, 400
circulatory overload, 401
citrated toxicity, 399–400
electrolyte and acid–base imbalance, 400
embolism, 401
hypothermia, 399
iron overload, 401
nonimmunologic hemolysis, 384
passenger lymphocyte-related hemolysis, 383–4
platelet transfusions, 388
signs and symptoms of, 391–392, 392t, 393t
treatment of, 394
passive transfer of hypersensitivity, 401
See also Transfusion-related immunomodulation (TRIM)
Transfusion-associated graft-versus
host disease (TA-GVHD), 281, 463–465
Transfusion-associated microchimerism (TAMC), 399
Transfusion-related acute lung injury (TRALI), 166, 377, 385, 386,
386t, 461, 466
Transfusion-related immunomodulation (TRIM), 249, 396
Transfusion-transmitted diseases,
413t, 414t, 422t
bacterial, 427
parasitic and tick-borne, 427–30
viruses, 422–427
estimates of (in US), 414t
screening, 156t
bacterial infections
leishmaniasis, 430
parasitic diseases, 428–429
tick-borne diseases, 429–430
chikungunya virus, 425, 426
current issues with
bovine spongiform encephalopathy, 430–431
variant Creutzfeldt–Jakob disease (vCJD), 83, 430–431
cytomegalovirus (CMV), 423
dengue virus, 427
Transfusion-transmitted diseases (cont’d)

Epstein–Barr virus (EBV), 425
hepatitis, 413–15
hepatitis A virus (HAV), 415
hepatitis B virus (HBV), 415–417, 416f
hepatitis C, 418
hepatitis E virus (HEV), 419
hepatitis G, 418–419
non-A, non-B hepatitis and surrogate testing, 417–418
SEN virus, 419
surrogate testing, 417–418
TT virus (TTV), 419
HIV infection and AIDS, 410, 420f
anti-HIV-negative blood (window phase), transfusion of, 421
anti-HIV-1-positive blood, transfusion of, 422
HIV-1 antibody tests, 421
HIV antigen testing, 421
HIV laboratory screening tests, 420
nucleic acid amplification testing, 421
transfusion on AIDS, effect of, 422
Human herpesvirus 6 (HHV-6)/Human herpesvirus 8 (HHV-8), 426
human T-lymphotrophic virus I and II, 423–424
influenza, 431
parvovirus, 424–425
screening tests (new), 432–433, 432t
simian foamy virus, 427
syphilis, 412–413
toscana virus, 426
West Nile virus (WNV), 425
xenotropic murine leukemia virus-related virus (XMRV), 431
Zika virus, 425–426
Transmissible diseases testing, 14
See also Laboratory testing of donated blood
Transport protein, 199
TRAP study, 274
T-regulatory cells, 504–505

Treponema pallidum, 163, 413
Tri-n-butyl-phosphate (TNBP), 84
Triton X100, 87
Trypanosoma cruzi, 164, 428–429
See also trypanosomiasis
TT virus (TTV), 419
Tube tests, 214
Tullis, James, 123
Tumor cell purging, 500
Tumor vaccines (translational development), 495t

Ultraviolet B (UVB) irradiation, 463, 464
Ultraviolet-irradiated platelets, 274
Umbilical cord blood (UCB), 497, 499–500
banking See Cellular engineering and cord blood
Uncrossmatched red cells, 229–230
United Network for Organ Sharing (UNOS), 457
United States Federal Regulation of blood supply system, 23–25
United States blood supply, 15–16
Universal red cells, 89
enzymatic cleavage of ABO and Rh antigen, 89–90
Urticaria, autoimmune, 535

Variant Creutzfeldt–Jakob disease (vCJD), 83, 430–431
Vascular access for plasma exchange, 535–536
Vasodilatation, 544
Vasovagal syndrome, 53
Vein selection, 50
Venipuncture, 51, 364
site preparation, 50, 50t
Venous access, 364
Viral testing, 158
Viremia, 415, 431
Virtual crossmatching, 455
Voluntary accreditation of blood banks, 25
Volunteerism, 33
VonWillebrand’s disease, 79, 261–262, 337–338
Vox Sanguinis (journal on blood transfusion), 23
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walter, Carl</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Washed red cells</td>
<td>75, 249–50</td>
<td></td>
</tr>
<tr>
<td>West Nile virus (WNV)</td>
<td>425</td>
<td></td>
</tr>
<tr>
<td>infection</td>
<td>163–164</td>
<td></td>
</tr>
<tr>
<td>Western blot</td>
<td>159</td>
<td></td>
</tr>
<tr>
<td>Whole blood donors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medical assessment of See Blood donors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>donor medical assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>motivation of See Blood donors,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>recruitment of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>recruitment strategies of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>34–35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whole blood, 247</td>
<td></td>
<td></td>
</tr>
<tr>
<td>collection of See Blood donor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medical assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>donation, adverse reactions to,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>52–55, 52t</td>
<td></td>
<td></td>
</tr>
<tr>
<td>anticoagulant preservative solutions, 50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>blood collection, 51–52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>blood containers, 49–50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>labeling, 49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>vein selection, 50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>venipuncture, 51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>venipuncture site preparation, 50, 50t</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wiener system, 182, 183t</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilson’s disease, 535</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Window phase, 158, 421</td>
<td></td>
<td></td>
</tr>
<tr>
<td>shortening of, 159–160</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolff, Andrei, 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Health Organization (WHO), 22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Worldwide blood supply, 13–15, 14t</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xenotropic murine leukemia virus-related</td>
<td></td>
<td></td>
</tr>
<tr>
<td>virus (XMRV), 431</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xg system, 192</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yersinia enterocolitica, 106, 389</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yudin’s Institute, 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zika virus, 425–426</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>